Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 2Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Prostatic Neoplasms 2Inflammation 2Stomach Neoplasms 1Pancreatic Neoplasms 1Pain, Postoperative 1Pain 1Gynecological Laparoscopic Surgery 1Esophageal Neoplasms 1Emergence Delirium 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Sorafenib 121Nivolumab 36pembrolizumab 32Bevacizumab 28lenvatinib 27Doxorubicin 23Radiosurgery 21Radiofrequency Ablation 20Oxaliplatin 20Hepatectomy 18Fluorouracil 15Capecitabine 15Magnetic Resonance Spectroscopy 14atezolizumab 13Leucovorin 13Cisplatin 13Gemcitabine 11Erlotinib Hydrochloride 11tislelizumab 9Sirolimus 9Radiotherapy 9Irinotecan 9Ipilimumab 9cabozantinib 8Liver Transplantation 8regorafenib 7Ramucirumab 7Folfox protocol 7Embolization, Therapeutic 7sintilimab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Hepatocellular × Sufentanil × Clear all
NCT06041425 2024-02-28

The Effects of Oxycodone Versus Sufentanil on Pain and Inflammatory Response After TACE

The First Affiliated Hospital with Nanjing Medical University

Phase 4 Completed
40 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Inflammation, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡